NSPR Stock - InspireMD, Inc.
Unlock GoAI Insights for NSPR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.01M | $6.21M | $5.17M | $4.50M | $2.48M |
| Gross Profit | $1.51M | $1.81M | $1.12M | $754,000 | $83,000 |
| Gross Margin | 21.5% | 29.1% | 21.6% | 16.8% | 3.3% |
| Operating Income | $-33,503,000 | $-21,143,000 | $-18,713,000 | $-14,716,000 | $-10,380,000 |
| Net Income | $-32,005,000 | $-19,916,000 | $-18,491,000 | $-14,918,000 | $-10,544,000 |
| Net Margin | -456.6% | -321.0% | -357.6% | -331.9% | -424.3% |
| EPS | $-0.76 | $-0.82 | $-2.35 | $-2.03 | $-6.90 |
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Visit WebsiteEarnings History & Surprises
NSPREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | $-0.22 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.17 | $-0.17 | 0.0% | = MET |
Q3 2025 | Aug 4, 2025 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q2 2025 | May 9, 2025 | $-0.17 | $-0.22 | -29.4% | ✗ MISS |
Q1 2025 | Mar 12, 2025 | $-0.20 | $-0.19 | +5.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.19 | $-0.22 | -15.8% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.15 | $-0.21 | -40.0% | ✗ MISS |
Q1 2024 | Mar 6, 2024 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-0.17 | $-0.15 | +11.8% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.17 | $-0.24 | -41.2% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.68 | $-0.53 | +22.1% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $0.84 | $-0.60 | -171.4% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.73 | $-0.58 | +20.5% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.73 | $-0.59 | +19.2% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.80 | $-0.57 | +28.8% | ✓ BEAT |
Q1 2022 | Mar 8, 2022 | $-0.78 | $-0.53 | +32.1% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | — | $-0.53 | — | — |
Q3 2021 | Aug 10, 2021 | — | $-0.46 | — | — |
Latest News
InspireMD CREST-2 Data Demonstrates Addition Of Stenting Improves Outcomes In Trial For Participants With Asymptomatic Carotid Stenosis
📈 PositiveInspireMD Q3 EPS $(0.17) Beats $(0.23) Estimate, Sales $2.523M Beat $1.760M Estimate
📈 PositiveInspireMD raises $58M through combined financings; shares up
📈 PositiveFrequently Asked Questions about NSPR
What is NSPR's current stock price?
What is the analyst price target for NSPR?
What sector is InspireMD, Inc. in?
What is NSPR's market cap?
Does NSPR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NSPR for comparison